<DOC>
	<DOCNO>NCT01732471</DOCNO>
	<brief_summary>This open-label , non-comparative , Phase 3 study evaluate degree , frequency response safety Kuvan速 ( sapropterin dihydrochloride ) subject age 4 18 year phenylketonuria elevate blood phenylalanine level great equal 450 micromole per liter .</brief_summary>
	<brief_title>Phase 3 Open-label Study Evaluate Response Safety Kuvan速 Subjects With Phenylketonuria</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Willing able provide write informed consent ( child 18 year old parent [ ] /guardians give inform consent , subject 1417 year old give additionally write informed consent ) Age 4 18 year , inclusive Confirmed clinical biochemical hyperphenylalaninemia due phenylketonuria document past medical history least 2 blood phenylalanine level great equal 400 micromole per liter obtain 2 separate occasion Blood phenylalanine level screen great equal 450 micromole per liter ( mean two measurement ) For woman childbearing potential , negative urine pregnancy test require screening willingness use highly effective method contraception require participate study Subject and/or parent/guardian willing able comply study procedure Subject and/or parent/guardian willing continue current diet unchanged 8 day response test adapt diet accord phenylalanine therapeutic target range 6 week treatment period Subject already assess responsiveness sapropterin dihydrochloride tetrahydrobiopterin ( BH4 ) Used investigational agent Kuvan速 ( sapropterin dihydrochloride ) within 30 day screen , require investigational agent vaccine prior completion schedule study assessment Pregnant breastfeeding , consider pregnancy Concurrent disease condition would interfere study participation safety ( example , seizure disorder , asthma condition require oral parenteral corticosteroid administration , insulindependent diabetes , organ transplantation recipient ) Concurrent use require concomitant treatment drug know inhibit folate synthesis ( example , methotrexate ) , levodopa , phosphodiesterase type5 ( PDE5 ) inhibitor ( , sildenafil , vardenafil tadalafil ) , medication know affect nitric oxide synthesis metabolism action Any condition , , view Principal Investigator render subject high risk failure comply treatment complete study Clinical diagnosis primary BH4 deficiency Known hypersensitivity Kuvan速 ( sapropterin dihydrochloride ) excipients approve nonapproved formulation tetrabiopterin</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>EMR 700733_510 , Genetic disorder , Phenylketonuria , phenylalanine , Kuvan , sapropterin dihydrochloride</keyword>
</DOC>